Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul 15;402(10397):160-161.
doi: 10.1016/S0140-6736(23)01058-9. Epub 2023 Jun 5.

Sequencing checkpoint inhibitor therapy in renal cell carcinoma

Kathryn E Beckermann  1 , Brian I Rini  2
Affiliations
Comment

Sequencing checkpoint inhibitor therapy in renal cell carcinoma

Kathryn E Beckermann et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

KEB declares funding to their institution for clinical trials from Aveo, BMS, Exelixis, Arrowhead, Aravive, and Merck; receives research funding to the institution for preclinical research from Aravive, Arsenal, BMS-LCFA-IASLC, and Pionyr; and has received consulting fees from Aveo, BMS, Exelixis, Astrazeneca, Alpine Bioscience, Aravive, Merck, Sanofi, and Seagen, outside the scope of the submitted work. BIR declares institutional funding from Exelixis, AVEO, Genentech, BMS, Arcus, Merck, Dragonfly Therapeutics, HiberCell, Incyte, Stata Oncology, ADC Therapeutics, Dracen Pharmaceuticals, Janssen, Adela, AstraZeneca, Pionyr, Tempus, VasGene Therapeutics, Gilead, POINT Biopharma, Pfizer, Daiichi Sankyo, Arrowhead Pharmaceuticals, Exelixis, Surface Oncology, and Aravive; has received consulting fees from BMS, Genentech, AVEO and Exelixis, Pfizer, Synthorx, Merck, Corvus, Surface Oncology, Aravive, Alkermes, Arrowhead, Eisai, Nikang Therapeutics, EUSA, Athenex, Debiopharm, and HiberCell; declares previously owned stocks (within the past year) in PTC Therapeutics, a company with approved and pipeline products in muscular dystrophy, metabolic disorders, diffuse intrinsic pontine glioma, and leiomyosarcoma unrelated to the oncology indication discussed here.

Comment on

Similar articles

See all similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources